3D-printed drug approved for epilepsy treatment
06 August, 2015A 3D-printed drug product has been approved by the US FDA for the treatment of partial onset seizures, myoclonic seizures and primary generalised tonic-clonic seizures in adults and children with epilepsy.
Adherium launches IPO prior to ASX listing
05 August, 2015Digital health technology manufacturer Adherium is seeking to raise a maximum of $35 million in the lead-up to its listing on the ASX.
Bionomics appoints chief business officer
03 August, 2015Bionomics Chief Business Officer Tony Colasin will lead corporate development for the company, including business development and strategic opportunities.
ResMed to acquire Curative Medical
31 July, 2015Sleep disorder device supplier ResMed has signed a definitive agreement to acquire its Chinese counterpart Curative Medical.
Manufacturing MSCs to treat heart disease
30 July, 2015Cynata Therapeutics is collaborating with the University of Sydney to test the potential therapeutic efficacy of its Cymerus mesenchymal stem cells (MSCs) in animal models of heart attack and associated heart rhythm abnormalities.
Call for a strategic effort towards advanced manufacturing
30 July, 2015Australia is in the position to secure a globally competitive, locally based advanced manufacturing sector, according to CSL CFO Gordon Naylor.
Ethnic diversity and global drug development
29 July, 2015 by GlaxoSmithKlineOngoing research by GSK’s Ethnopharmacology Group led by Dr Annette Gross is investigating the potential for inter-ethnic differences in response to new medicines being developed by GSK R&D.
Reformulating an asthma drug for inhalation
27 July, 2015Invion and Hovione Scientia will partner on the development of inhaled INV104 (zafirlukast) as a potential new treatment for asthma. INV104 is a leukotriene receptor antagonist which works by blocking the action of leukotrienes in the lungs, thereby preventing inflammation and narrowing of the airways.
Digital health technology to manage respiratory diseases
23 July, 2015Under a long-term supply agreement, Adherium will supply innovative new devices that AstraZeneca will incorporate within patient support programs for patients with chronic obstructive pulmonary disease and asthma.
$40 million in financing to advance oral peptide drugs
22 July, 2015Protagonist Therapeutics has announced the closing of a $40 million Series C financing, the proceeds of which will be used to further the development of the company's oral peptide drug candidates.
Developing a platform for macrocyclic drugs
17 July, 2015Phylogica and the Institute for Molecular Bioscience have been awarded a $670,000 Linkage grant to develop a novel platform to generate macrocyclic peptide libraries.
Orthocell regenerates cartilage within joints
16 July, 2015An international research paper provides peer-reviewed support for Orthocell's new approach to the regeneration of damaged cartilage within joints.
AstraZeneca and Adelaide collaborate on drug discovery
13 July, 2015AstraZeneca's agreement with Adelaide Research and Innovation will provide an opportunity for researchers at the University of Adelaide to collaborate with industry-leading scientists to develop new medicines.
Grant to progress tendon fabrication project
09 July, 2015Orthocell has received an ARC grant of $430,000 to continue its investigation of tendon tissue and the development of novel therapies — such as the laboratory-fabricated tendon project announced by the company late last year.
Spinifex Pharmaceuticals sold to Novartis
08 July, 2015 by Susan WilliamsonAustralian biotech Spinifex Pharmaceuticals will be bought by global healthcare company Novartis for US$200 million.
